AU2004230254B2 - Chimeric polypeptides and their use - Google Patents

Chimeric polypeptides and their use Download PDF

Info

Publication number
AU2004230254B2
AU2004230254B2 AU2004230254A AU2004230254A AU2004230254B2 AU 2004230254 B2 AU2004230254 B2 AU 2004230254B2 AU 2004230254 A AU2004230254 A AU 2004230254A AU 2004230254 A AU2004230254 A AU 2004230254A AU 2004230254 B2 AU2004230254 B2 AU 2004230254B2
Authority
AU
Australia
Prior art keywords
cells
dna
polypeptide
cell
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004230254A
Other languages
English (en)
Other versions
AU2004230254A1 (en
Inventor
Christian Kuhne
Andras Simoncsits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADRIACELL SpA
Original Assignee
ADRIACELL SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADRIACELL SpA filed Critical ADRIACELL SpA
Publication of AU2004230254A1 publication Critical patent/AU2004230254A1/en
Application granted granted Critical
Publication of AU2004230254B2 publication Critical patent/AU2004230254B2/en
Assigned to ADRIACELL S.P.A. reassignment ADRIACELL S.P.A. Request for Assignment Assignors: INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
AU2004230254A 2003-04-18 2004-04-16 Chimeric polypeptides and their use Ceased AU2004230254B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000821A ITMI20030821A1 (it) 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso.
ITMI2003A000821 2003-04-18
PCT/EP2004/004062 WO2004092194A2 (en) 2003-04-18 2004-04-16 Chimeric polypeptides and their use

Publications (2)

Publication Number Publication Date
AU2004230254A1 AU2004230254A1 (en) 2004-10-28
AU2004230254B2 true AU2004230254B2 (en) 2008-10-02

Family

ID=33187374

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004230254A Ceased AU2004230254B2 (en) 2003-04-18 2004-04-16 Chimeric polypeptides and their use

Country Status (16)

Country Link
US (3) US20060292629A1 (enExample)
EP (1) EP1616011B1 (enExample)
JP (2) JP4794432B2 (enExample)
KR (2) KR101360781B1 (enExample)
CN (1) CN100584950C (enExample)
AT (1) ATE374826T1 (enExample)
AU (1) AU2004230254B2 (enExample)
CA (1) CA2522525A1 (enExample)
CY (1) CY1107115T1 (enExample)
DE (1) DE602004009301T2 (enExample)
DK (1) DK1616011T3 (enExample)
ES (1) ES2293247T3 (enExample)
IT (1) ITMI20030821A1 (enExample)
PL (1) PL1616011T3 (enExample)
PT (1) PT1616011E (enExample)
WO (1) WO2004092194A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
JP2008530575A (ja) * 2005-02-18 2008-08-07 アストラゼネカ アクチボラグ Ｃｈｋ１阻害薬に対する応答性を判定する方法
GB0609119D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Histones
WO2008141096A2 (en) * 2007-05-11 2008-11-20 The Regents Of The University Of California Nucleic acids for inducing expression of transcripts and proteins and methods for making and using them
HK1231556A1 (zh) 2014-02-17 2017-12-22 克劳德贝尔纳里昂第一大学 确定组织放射敏感性的预测方法
CN104193826B (zh) * 2014-09-17 2018-02-23 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用
WO2017178885A2 (en) * 2016-04-12 2017-10-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methylmalonyl coenzyme a mutase (mcm) fusion constructs for the treatment of disorders associated with mcm deficiency
JP6925003B2 (ja) * 2016-05-10 2021-08-25 公立大学法人横浜市立大学 非相同末端連結欠損細胞及びその利用
EP4269427A3 (en) 2016-05-27 2023-11-22 Synthex, Inc. Protein interfaces
EP3469070B1 (en) * 2016-06-09 2021-08-04 Alma Mater Studiorum - Università di Bologna Herpesvirus with modified glycoprotein b
MY200418A (en) 2017-06-15 2023-12-25 Univ California Targeted non-viral dna insertions
SG11202003798TA (en) 2017-10-27 2020-05-28 Univ California Targeted replacement of endogenous t cell receptors
WO2019104244A1 (en) 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
AU2022409717A1 (en) 2021-12-16 2024-05-30 Pags Co., Ltd. Cell penetrating polypeptides (cpps) and their use in human therapy
CN116023512A (zh) * 2023-02-16 2023-04-28 浙江大学 一条靶向dna损伤修复蛋白的多肽及其用途
EP4480497A1 (en) 2023-06-21 2024-12-25 RDP Pharma AG Bio-conjugates for oncology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
AU2982900A (en) * 1999-02-03 2000-08-25 Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
AU775001B2 (en) * 1999-03-31 2004-07-15 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
WO2001074905A1 (en) * 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
US9447434B2 (en) * 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DONAHUE S. L. ET AL. "Mitochondrial DNA ligase function in Saccharomyces cerevisiae." Nucleic Acids research, 2001, vol. 29, no. 7, pages 1582-1589 *
NISHIGORI C ET AL. "HindIII liposomes suppress delayed-type hypersensitivity responses in vivo and induce epidermal IL-10 in vitro." The Journal of Immunology, 1998, vol. 161, pages 2684-2691 *
ROSENBERG A ET AL. "T7Select phage display system: a powerful new protein display system based on bacteriophage T7." Innovations, December 1996, no. 6, pages 1-6 *
TANAKA M ET AL. "Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria." Journal of Biomedical Science, 2002, vol 9, pages 534-541 *

Also Published As

Publication number Publication date
JP4794432B2 (ja) 2011-10-19
CN1768142A (zh) 2006-05-03
ITMI20030821A1 (it) 2004-10-19
KR20110074948A (ko) 2011-07-04
JP2011182792A (ja) 2011-09-22
CY1107115T1 (el) 2012-01-25
EP1616011A2 (en) 2006-01-18
WO2004092194A2 (en) 2004-10-28
US20060292629A1 (en) 2006-12-28
US20110033384A1 (en) 2011-02-10
JP2006523448A (ja) 2006-10-19
ATE374826T1 (de) 2007-10-15
CA2522525A1 (en) 2004-10-28
CN100584950C (zh) 2010-01-27
PL1616011T3 (pl) 2008-05-30
PT1616011E (pt) 2008-01-07
DK1616011T3 (da) 2008-02-04
DE602004009301D1 (de) 2007-11-15
DE602004009301T2 (de) 2008-07-17
KR101247704B1 (ko) 2013-03-26
ES2293247T3 (es) 2008-03-16
WO2004092194A3 (en) 2005-03-17
KR20060003029A (ko) 2006-01-09
EP1616011B1 (en) 2007-10-03
US20150018409A1 (en) 2015-01-15
KR101360781B1 (ko) 2014-04-24
AU2004230254A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
US20110033384A1 (en) Chimeric polypeptides and their use
JP6867440B2 (ja) 三構成要素ＣＲＩＳＰＲ／Ｃａｓ複合体系およびその使用
Huber et al. A conserved G4 DNA binding domain in RecQ family helicases
Costantini et al. Interaction of the Ku heterodimer with the DNA ligase IV/Xrcc4 complex and its regulation by DNA-PK
Zheng et al. Human DNA2 is a mitochondrial nuclease/helicase for efficient processing of DNA replication and repair intermediates
KR20200017479A (ko) Crispr/cas 활성제 시스템용 합성 유도 rna
EP2526199A2 (en) Methods of generating zinc finger nucleases having altered activity
WO1996012820A1 (en) INTERACTIONS BETWEEN Raf PROTO-ONCOGENES AND CDC25 PHOSPHATASES, AND USES RELATED THERETO
Choi et al. Meiosis-specific cohesin complexes display essential and distinct roles in mitotic embryonic stem cell chromosomes
US20120329067A1 (en) Methods of Generating Zinc Finger Nucleases Having Altered Activity
CN112930398A (zh) 新的核酸酶结构域及其利用
Yan et al. Analysis of the Xenopus Werner syndrome protein in DNA double-strand break repair
US20190048048A1 (en) Fusion proteins and methods for identifying bromodomain inhibiting compounds
Sugaya et al. A temperature-sensitive mutation in the WD repeat-containing protein Smu1 is related to maintenance of chromosome integrity
EP3702495A1 (en) Antibody like protein
Miller et al. Nuclear localization of Rad51B is independent of Rad51C and BRCA2
Kulepa Probing interactions of the BRCT protein family with damaged chromatin
Zappone Role of SFPQ function in RNA: DNA hybrids related genomic instability in telomeres
Wu Roles of NBS1 and BRCA2 cancer susceptibility genes in the maintenance of genome stability
Bonalli Investigations on phosphospecific interactions in the DNA damage response
Hoellerich et al. Nucleolar localization of SmMAK16 protein from Schistosoma mansoni is regulated by three distinct signals that function independent of pH or phosphorylation status
Islam Development of Systems for Expression, Purification, and CK2-Mediated Phosphorylation of the Histone Oligomers
ES2363398A1 (es) Métodos y composiciones para la identificación de compuestos embriotóxicos.
Sigvaldadóttir Functional analysis of the dREQ MITF mutant: Determination of the nuclear localization and transcription activation potential of an MITF mutant lacking three amino acids
홍명진 RecQL4 interacts with MRN complex to regulate DNA damage response

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ADRIACELL S.P.A.

Free format text: FORMER OWNER WAS: INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY

MK14 Patent ceased section 143(a) (annual fees not paid) or expired